Immunogenicity associated with the routine use of an influenza A H1N1 vaccine in health care personnel in Guangzhou, China

Clinical and Vaccine Immunology

Volumn 17, Issue 9, 2010, Pages 1478-1480

  Di, Biao ^a   Xu, Xinhong ^a   Li, Tiegang ^a   Lu, Enjie ^a   Wu, Jibin ^a   Liu, Yanhui ^a   Chen, Yiyun ^a   Pickerill, Sam ^b   Wang, Ming ^a  

^a GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Ustar Biotechnologies (Hangzhou) Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MALE; PRIORITY JOURNAL;

ADULT; ANTIBODIES, VIRAL; CHINA; FEMALE; HEALTH PERSONNEL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED;

EID: 77956404590     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00137-10     Document Type: Article

References (10)

1. European Committee for Proprietary Medicinal Products. 1997. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
2. Fiore, A. E., D. K. Shay, K. Broder, J. K. Iskander, T. M. Uyeki, G. Mootrey, J. S. Bresee, and N. S. Cox. 2008. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recommend. Rep. 57:1-60.
3. Greenberg, M. E., M. H. Lai, G. F. Hartel, C. H. Wichems, C. Gittleson, J. Bennet, G. Dawson, W. Hu, C. Leggio, D. Washington, and R. L. Basser. 2009. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361:2405-2413.
4. Kendal, A. P., M. S. Pereira, and J. J. Skehel. 1982. Concepts and procedures from laboratory-based influenza surveillance. Centers for Disease Control and Prevention, Atlanta, GA.
5. Liang, X. F., H. Q. Wang, J. Z. Wang, H. H. Fang, J. Wu, F. C. Zhu, R. C. Li, S. L. Xia, Y. L. Zhao, F. J. Li, S. H. Yan, W. D. Yin, K. An, D. J. Feng, X. L. Cui, F. C. Qi, C. J. Ju, Y. H. Zhang, Z. J. Guo, P. Y. Chen, Z. Chen, K. M. Yan, and Y. Wang. 2010. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375:56-66.
6. McConnell, J. 2009. Influenza in the Asia-Pacific. Lancet Infect. Dis. 9:590-591.
7. Plennevaux, E., E. Sheldon, M. Blatter, M. K. Reeves-Hoché, and M. Denis. 2010. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 375:41-48.
8. Shetty, P. 2010. H1N1 vaccine access and excess. Lancet Infect. Dis. 10:75.
9. WHO. 2010. Pandemic (H1N1) 2009 - update 89. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/don/2010-02-26/en/index.html.
10. Zhu, F.-C., H. Wang, H.-H. Fang, J. G. Yang, X. J. Lin, X.-F. Liang, X.-F. Zhang, H.-X. Pan, F.-Y. Meng, Y. M. Hu, W.-D. Liu, C.-G. Li, W. Li, X. Zhang, J. M. Hu, W. B. Peng, B. P. Yang, P. Xi, H.-Q. Wang, and J.-S. Zheng. 2009. A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med. 361:2414-2423.